Experimental gene therapy tested in duchenne boys with immune barriers – study stopped early

NCT ID NCT06597656

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 22 times

Summary

This early-stage study tested a gene therapy (delandistrogene moxeparvovec) in 3 boys with Duchenne muscular dystrophy who had pre-existing antibodies that could block the therapy. To overcome this, the boys first received a procedure called plasmapheresis to remove those antibodies. The main goals were to check safety and see if the therapy could produce the missing dystrophin protein. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States

  • University of Florida, College of Medicine

    Gainesville, Florida, 32610, United States

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.